

Seth L Bauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2595702/publications.pdf>

Version: 2024-02-01

77
papers

1,319
citations

331259

21
h-index

395343

33
g-index

77
all docs

77
docs citations

77
times ranked

1631
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemodynamic Response to Vasopressin Dosage of 0.03 Units/Min vs. 0.04 Units/Min in Patients With Septic Shock. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 92-99.	1.3	5
2	Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock*. <i>Critical Care Medicine</i> , 2022, 50, 614-623.	0.4	56
3	Association Between Vasopressin Rebranding and Utilization in Patients With Septic Shock*. <i>Critical Care Medicine</i> , 2022, 50, 644-654.	0.4	13
4	Association of Arterial pH With Hemodynamic Response to Vasopressin in Patients With Septic Shock: An Observational Cohort Study. , 2022, 4, e0634.		9
5	Association of Methylene Blue Dosing with Hemodynamic Response for the Treatment of Vasoplegia. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, , .	0.6	3
6	Effect of Phenylephrine Push Before Continuous Infusion Norepinephrine in Patients With Septic Shock. <i>Chest</i> , 2021, 159, 1875-1883.	0.4	13
7	Response. <i>Chest</i> , 2021, 159, 878-879.	0.4	0
8	Author's Response: Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock. <i>Shock</i> , 2021, 56, 870.	1.0	0
9	The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. <i>Critical Care Medicine</i> , 2021, 49, 598-622.	0.4	49
10	Ethanol Exposure Attenuates Immune Response in Sepsis via Sirtuin 2 Expression. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 338-350.	1.4	5
11	Critical care essentials for pharmacy trainees and new clinical practitioners. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1176-1183.	0.5	2
12	Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock. <i>Shock</i> , 2021, 55, 210-214.	1.0	8
13	Corticosteroids for Septic Shock: Another Chapter in the Saga. <i>Hospital Pharmacy</i> , 2020, 55, 135-142.	0.4	5
14	Association Between Volume of Fluid Resuscitation and Intubation in High-Risk Patients With Sepsis, Heart Failure, End-Stage Renal Disease, and Cirrhosis. <i>Chest</i> , 2020, 157, 286-292.	0.4	38
15	Cost-effectiveness of second-line vasopressors for the treatment of septic shock. <i>Journal of Critical Care</i> , 2020, 55, 48-55.	1.0	12
16	Vasopressin Plasma Concentrations Are Not Associated with Hemodynamic Response to Exogenous Vasopressin for Septic Shock. <i>Pharmacotherapy</i> , 2020, 40, 33-39.	1.2	15
17	Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series Analysis. <i>Annals of Pharmacotherapy</i> , 2020, 54, 314-321.	0.9	9
18	Effectiveness, Safety, and Economic Comparison of Inhaled Epoprostenol Brands, Flolan and Veletri, in Acute Respiratory Distress Syndrome. <i>Annals of Pharmacotherapy</i> , 2020, 54, 434-441.	0.9	6

#	ARTICLE	IF	CITATIONS
19	Effectiveness and Safety of Twice Daily Versus Thrice Daily Subcutaneous Unfractionated Heparin for Venous Thromboembolism Prophylaxis at a Tertiary Medical Center. <i>Journal of Pharmacy Practice</i> , 2020, , 089719002096121.	0.5	2
20	Association Between Compliance With the Sepsis Quality Measure (SEP-1) and Hospital Readmission. <i>Chest</i> , 2020, 158, 608-611.	0.4	5
21	Inpatient Initiation of Oral Treprostinil in an Academic Medical System. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 547-553.	1.3	1
22	What is the role of supplementation with ascorbic acid, zinc, vitamin D, or <i>N</i> -acetylcysteine for prevention or treatment of COVID-19?. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	0.6	51
23	Bispectral Index for Titrating Sedation in ARDS Patients During Neuromuscular Blockade. <i>American Journal of Critical Care</i> , 2019, 28, 377-384.	0.8	11
24	Perceptions regarding vasopressin use and practices in septic shock, and cost containment strategies. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 257-267.	0.5	10
25	Optimal norepinephrine-equivalent dose to initiate epinephrine in patients with septic shock. <i>Journal of Critical Care</i> , 2019, 53, 69-74.	1.0	4
26	Educational Targets to Reduce Medication Errors by General Surgery Residents. <i>Journal of Surgical Education</i> , 2019, 76, 1612-1621.	1.2	6
27	Effects of Norepinephrine and Vasopressin Discontinuation Order in the Recovery Phase of Septic Shock: A Systematic Review and Individual Patient Data Meta-Analysis. <i>Pharmacotherapy</i> , 2019, 39, 544-552.	1.2	19
28	Continuous Medical Education Changes Practice: One Year After SMART and SALT-ED. , 2019, 1, e0017.		4
29	Inter-rater Agreement for Abstraction of the Early Management Bundle, Severe Sepsis/Septic Shock (SEP-1) Quality Measure in a Multi-Hospital Health System. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2019, 45, 108-111.	0.4	4
30	Vasoactive Agent Use in Septic Shock: Beyond First-Line Recommendations. <i>Pharmacotherapy</i> , 2019, 39, 369-381.	1.2	19
31	Frequency, Timing, and Types of Medication Ordering Errors Made by Residents in the Electronic Medical Records Era. <i>Southern Medical Journal</i> , 2019, 112, 25-31.	0.3	11
32	Effectiveness of venous thromboembolism prophylaxis in patients with liver disease. <i>World Journal of Hepatology</i> , 2019, 11, 379-390.	0.8	14
33	Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock. <i>Pharmacotherapy</i> , 2018, 38, 319-326.	1.2	24
34	Systematic Review and Meta-Analysis of Procalcitonin-Guidance Versus Usual Care for Antimicrobial Management in Critically Ill Patients: Focus on Subgroups Based on Antibiotic Initiation, Cessation, or Mixed Strategies*. <i>Critical Care Medicine</i> , 2018, 46, 684-690.	0.4	66
35	Body Mass's Impact on Response to Fixed-Dose Vasopressin in Patients With Septic Shock. <i>Shock</i> , 2018, 50, 388-394.	1.0	7
36	1398: EFFECT OF BASELINE PH ON VASOPRESSIN RESPONSE IN PATIENTS WITH SEPTIC SHOCK. <i>Critical Care Medicine</i> , 2018, 46, 683-683.	0.4	1

#	ARTICLE	IF	CITATIONS
37	1401: THE GOLDILOCKS ZONE: VASOPRESSIN RESPONSE IS DEPENDENT ON ADMISSION LACTATE AND TIMING OF INITIATION. <i>Critical Care Medicine</i> , 2018, 46, 684-684.	0.4	28
38	Effectiveness, safety, and Economic Comparison of Two Inhaled Epoprostenol Products (Flolan and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 8.9	0.9	7
39	A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland Clinic. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 186-192.	1.0	36
40	Predictors of response to fixed-dose vasopressin in adult patients with septic shock. <i>Annals of Intensive Care</i> , 2018, 8, 35.	2.2	71
41	Safe Use of Vasopressin and Angiotensin <scp>ll</scp> for Patients with Circulatory Shock. <i>Pharmacotherapy</i> , 2018, 38, 851-861.	1.2	18
42	Development of the Critical Care Pharmacotherapy Trials Network. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 287-293.	0.5	4
43	Compliance with Procalcitonin Algorithm Antibiotic Recommendations for Patients in Medical Intensive Care Unit. <i>Pharmacotherapy</i> , 2017, 37, 177-186.	1.2	7
44	Perceived safety and efficacy of neuromuscular blockers for acute respiratory distress syndrome among medical intensive care unit practitioners: A multicenter survey. <i>Journal of Critical Care</i> , 2017, 38, 278-283.	1.0	17
45	Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamineâ€œ Receptor Antagonists. <i>Pharmacotherapy</i> , 2017, 37, 1507-1515.	1.2	7
46	Institutional care paths: Development, implementation, and evaluation. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 1486-1493.	0.5	0
47	Antimicrobial Monotherapy versus Combination Therapy for the Treatment of Complicated Intra-Abdominal Infections. <i>Pharmacotherapy</i> , 2016, 36, 1138-1144.	1.2	13
48	Evaluation of an updated insulin infusion protocol at a large academic medical center. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, S88-S93.	0.5	4
49	Initial Care for Patients with Severe Sepsis and Septic Shock: The Next ICU Quality Measure. <i>Hospital Pharmacy</i> , 2016, 51, 19-25.	0.4	3
50	Procalcitonin-based algorithms to initiate or stop antibiotic therapy in critically ill patients: Is it time to rethink our strategy?. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 20-27.	1.1	11
51	Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 431-436.	1.4	33
52	Did the beneficial renal outcomes with vasopressin VANISH?. <i>Annals of Translational Medicine</i> , 2016, 4, S67-S67.	0.7	4
53	Compliance With Institutional Antimicrobial Dosing Guidelines in Patients Receiving Continuous Venovenous Hemodialysis. <i>Journal of Pharmacy Practice</i> , 2015, 28, 380-386.	0.5	2
54	Liposomal bupivacaine versus continuous infusion bupivacaine via an elastomeric pump for the treatment of postoperative pain. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, S127-S132.	0.5	11

#	ARTICLE	IF	CITATIONS
55	Noninferiority of Inhaled Epoprostenol to Inhaled Nitric Oxide for the Treatment of ARDS. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1105-1112.	0.9	34
56	Impact of Combination Antimicrobial Therapy on Mortality Risk for Critically Ill Patients with Carbapenem-Resistant Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3748-3753.	1.4	30
57	Intensive Care Nurses' Knowledge About Use of Neuromuscular Blocking Agents in Patients With Respiratory Failure. <i>American Journal of Critical Care</i> , 2015, 24, 431-439.	0.8	13
58	Comparison of Oral Vancomycin Capsule and Solution for Treatment of Initial Episode of Severe <i>Clostridium difficile</i> Infection. <i>Journal of Pharmacy Practice</i> , 2015, 28, 183-188.	0.5	9
59	Lactic acidosis: Clinical implications and management strategies. <i>Cleveland Clinic Journal of Medicine</i> , 2015, 82, 615-624.	0.6	43
60	Risk Factors Associated with Bleeding After Alteplase Administration for Pulmonary Embolism: A Case-Control Study. <i>Pharmacotherapy</i> , 2014, 34, 818-825.	1.2	22
61	Pharmacokinetics and Pharmacodynamics of Imipenem and Meropenem in Critically Ill Patients Treated With Continuous Venovenous Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2014, 63, 170-171.	2.1	21
62	Effect of vancomycin dose on treatment outcomes in severe <i>Clostridium difficile</i> infection. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 553-558.	1.1	27
63	Association Between Colistin Dose and Microbiologic Outcomes in Patients With Multidrug-Resistant Gram-Negative Bacteremia. <i>Clinical Infectious Diseases</i> , 2013, 56, 398-404.	2.9	91
64	Continuation or Discontinuation of Statin Therapy Did Not Influence Patient Outcomes after the Development of Acute Respiratory Distress Syndrome. <i>ISRN Critical Care</i> , 2013, 2013, 1-8.	0.0	0
65	Predictors of septic shock in patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteremia. <i>International Journal of Infectious Diseases</i> , 2012, 16, e453-e456.	1.5	6
66	Pharmacokinetics and Pharmacodynamics of Piperacillin-Tazobactam in 42 Patients Treated with Concomitant CRRT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 452-457.	2.2	70
67	Detectability of Vasopressin in Continuous Venovenous Hemodialysis Effluent of Patients with Vasodilatory Shock Treated with Exogenous Arginine Vasopressin. <i>Pharmacotherapy</i> , 2011, 31, 857-862.	1.2	2
68	Therapeutic Drug Monitoring of Piperacillin-Tazobactam Using Spent Dialysate Effluent in Patients Receiving Continuous Venovenous Hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 557-560.	1.4	31
69	Discontinuation of vasopressin before norepinephrine increases the incidence of hypotension in patients recovering from septic shock: A retrospective cohort study. <i>Journal of Critical Care</i> , 2010, 25, 362.e7-362.e11.	1.0	29
70	Arginine Vasopressin for the Treatment of Septic Shock in Adults. <i>Pharmacotherapy</i> , 2010, 30, 1057-1071.	1.2	23
71	Effect of Body Mass Index on Bleeding Frequency and Activated Partial Thromboplastin Time in Weight-Based Dosing of Unfractionated Heparin: A Retrospective Cohort Study. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1073-1078.	1.4	23
72	Corticosteroids in acute lung injury and acute respiratory distress syndrome. <i>Critical Care Medicine</i> , 2009, 37, 2680-2681.	0.4	3

#	ARTICLE	IF	CITATIONS
73	Lack of an Effect of Body Mass on the Hemodynamic Response to Arginine Vasopressin During Septic Shock. <i>Pharmacotherapy</i> , 2008, 28, 591-599.	1.2	17
74	Effect of corticosteroids on arginine vasopressin-containing vasopressor therapy for septic shock: a case control study. <i>Journal of Critical Care</i> , 2008, 23, 500-506.	1.0	28
75	EFFECTS OF BODY WEIGHT ON HEMODYNAMIC RESPONSE TO ARGININE VASOPRESSIN DURING SEPTIC SHOCK.. <i>Critical Care Medicine</i> , 2006, 34, A106.	0.4	0
76	EFFECT OF CORTICOSTEROIDS ON TIME TO WITHDRAWAL OF ARGININE VASOPRESSIN-CONTAINING VASOPRESSOR THERAPY IN SEPTIC SHOCK.. <i>Critical Care Medicine</i> , 2006, 34, A106.	0.4	0
77	Lack of cross-reactivity to meropenem in a patient with an allergy to imipenem-cilastatin. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 173-175.	1.5	14